A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area (BSA) Moderate Plaque Psoriasis With Special Site Involvement
Latest Information Update: 29 May 2025
At a glance
- Drugs Guselkumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms SPECTREM
- Sponsors Janssen Research & Development
Most Recent Events
- 23 May 2025 Status changed from active, no longer recruiting to completed.
- 10 Jan 2025 Planned End Date changed from 26 May 2025 to 9 Apr 2025.
- 10 Jan 2025 Planned primary completion date changed from 28 Apr 2025 to 9 Apr 2025.